
STAAR Surgical (STAA) Stock Forecast & Price Target
STAAR Surgical (STAA) Analyst Ratings
Bulls say
Staar Surgical Co. is projected to achieve a revenue growth of 7% year-over-year in 2026, indicating a strong trajectory based on a normalized sales base of $146 million in 2025, supported by market growth and increasing market share in Implantable Collamer lenses (ICL). The company is expected to benefit from a successful domestic launch of the EVO product and enhanced adoption internationally, which can drive above-market volume growth while also improving the cost structure. Additionally, management has highlighted opportunities for margin improvement and long-term growth positioning, reinforcing a positive outlook on Staar Surgical's financial performance.
Bears say
Staar Surgical Co. faces a negative outlook primarily due to projected flat to declining revenue growth, heavily influenced by high inventory levels attributed to its new distributor in China, leading to significant sales hits in the upcoming quarters. The company’s earnings have also been adversely affected by macroeconomic conditions and risks associated with patients' ability to afford out-of-pocket expenses for their products, as well as potential losses in market share to more cost-effective alternatives. Additionally, ongoing geopolitical uncertainties concerning China's market exposure further compound the challenges impacting Staar Surgical's financial performance.
This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.
STAAR Surgical (STAA) Analyst Forecast & Price Prediction
Start investing in STAAR Surgical (STAA)
Order type
Buy in
Order amount
Est. shares
0 shares